Berotralstat
| Clinical data | |
|---|---|
| Trade names | Orladeyo |
| Other names | BCX7353, BCX-7353 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Plasma kallikrein inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C30H26F4N6O |
| Molar mass | 562.573 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Berotralstat, sold under the brand name Orladeyo, is a medication used to prevent attacks of hereditary angioedema. Berotralstat is a plasma kallikrein inhibitor. It is taken by mouth.
The most common side effects include abdominal pain, vomiting, diarrhea, back pain, and heartburn.
Berotralstat was approved for medical use in the United States in December 2020, and in the European Union in April 2021.